X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1230) 1230
Publication (124) 124
Newsletter (42) 42
Book Review (20) 20
Book Chapter (14) 14
Newspaper Article (10) 10
Magazine Article (6) 6
Conference Proceeding (3) 3
Dissertation (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pazopanib (1264) 1264
index medicus (675) 675
oncology (602) 602
humans (589) 589
sunitinib (438) 438
cancer (368) 368
female (337) 337
male (323) 323
middle aged (265) 265
metastasis (258) 258
sorafenib (258) 258
aged (245) 245
care and treatment (234) 234
renal cell carcinoma (219) 219
carcinoma, renal cell - drug therapy (218) 218
kidney neoplasms - drug therapy (202) 202
adult (197) 197
carcinoma, renal cell (194) 194
pyrimidines - therapeutic use (190) 190
sulfonamides - therapeutic use (187) 187
drug therapy (186) 186
research (185) 185
survival (181) 181
treatment outcome (180) 180
chemotherapy (179) 179
sarcoma (167) 167
bevacizumab (166) 166
antineoplastic agents - therapeutic use (165) 165
interferon-alpha (165) 165
pharmacology & pharmacy (157) 157
vascular endothelial growth factor (151) 151
double-blind (148) 148
trial (140) 140
angiogenesis (139) 139
kidney neoplasms - pathology (137) 137
analysis (131) 131
everolimus (130) 130
tumors (130) 130
therapy (127) 127
angiogenesis inhibitors - therapeutic use (126) 126
disease-free survival (126) 126
medicine & public health (122) 122
kidney cancer (121) 121
patients (121) 121
pyrimidines - adverse effects (119) 119
sulfonamides - adverse effects (118) 118
dosage and administration (113) 113
axitinib (112) 112
urology & nephrology (112) 112
endothelial growth-factor (110) 110
tyrosine kinase inhibitor (108) 108
angiogenesis inhibitors (107) 107
targeted therapy (107) 107
clinical trials (104) 104
prognosis (104) 104
efficacy (103) 103
renal-cell carcinoma (102) 102
aged, 80 and over (101) 101
health aspects (101) 101
tyrosine (100) 100
pyrimidines - administration & dosage (99) 99
sulfonamides - administration & dosage (98) 98
tyrosine kinase inhibitors (96) 96
carcinoma, renal cell - pathology (95) 95
protein kinase inhibitors - therapeutic use (92) 92
patient outcomes (91) 91
hematology, oncology and palliative medicine (86) 86
retrospective studies (85) 85
phase-ii (84) 84
cancer therapies (83) 83
antineoplastic agents - adverse effects (81) 81
carcinoma (79) 79
soft tissue sarcoma (79) 79
antineoplastic agents (78) 78
animals (77) 77
soft-tissue sarcoma (77) 77
metastases (76) 76
development and progression (74) 74
antimitotic agents (73) 73
open-label (72) 72
angiogenesis inhibitors - adverse effects (71) 71
article (71) 71
vegf (71) 71
antineoplastic combined chemotherapy protocols - therapeutic use (70) 70
complications and side effects (70) 70
neoplasms. tumors. oncology. including cancer and carcinogens (70) 70
pyrimidines - pharmacology (70) 70
young adult (70) 70
phase-iii trial (68) 68
safety (68) 68
immunotherapy (67) 67
neoplasm metastasis (67) 67
sulfonamides - pharmacology (65) 65
hypertension (64) 64
inhibitor (63) 63
expression (62) 62
sarcoma - drug therapy (62) 62
case report (60) 60
carcinoma, renal cell - secondary (59) 59
medical research (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1226) 1226
German (29) 29
French (21) 21
Russian (9) 9
Korean (7) 7
Hungarian (2) 2
Polish (2) 2
Spanish (2) 2
Czech (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e20649 - e20649
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2019, Volume 17, Issue 5, pp. 625 - 628
The past year has led to significant changes in systemic therapies used to treat soft tissue sarcomas, mainly dominated by the removal of the recently approved... 
PAZOPANIB | ONCOLOGY
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 07/2019, Volume 46, Issue 7, pp. e263 - e265
Journal Article
11/2013
Low Dose Metronomic (LDM) chemotherapy, combined with VEGF pathway inhibitors, is a highly effective strategy to coordinately inhibit angiogenesis and tumor... 
Angiogenesis | Pediatric cancer | 0992 | Metronomic topotecan | Pazopanib
Dissertation
Internal Medicine, ISSN 0918-2918, 2018
The clinical efficacy and outcomes of pazopanib treatment for metastatic extraosseous Ewing sarcoma remain unclear. We herein report a case of heavily... 
extraosseous Ewing sarcoma | pazopanib
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 07/2016, Volume 142, Issue 1, pp. 89 - 94
Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They have a high recurrence rate following surgery, modest... 
Soft tissue sarcoma | Uterine sarcoma | Pazopanib
Journal Article
The Korean Journal of Internal Medicine, ISSN 1226-3303, 2018, Volume 33, Issue 2, p. 442
Journal Article
European Urology, ISSN 0302-2838, 12/2018, Volume 74, Issue 6, pp. 841 - 841
Journal Article
Journal of Gynecologic Oncology (JGO), ISSN 2005-0380, 2018, Volume 29, Issue 1, p. 1
Objective: In the treatment of metastatic soft tissue sarcoma (STS), pazopanib is considered a standard treatment after failure of chemotherapy. We... 
Sarcoma; Uterus; Endometrium; Pazopanib
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 8/2017, Volume 23, Issue 15, pp. 4027 - 4034
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 16, pp. 1588 - 1593
Purpose Standard frontline treatment of patients with metastatic renal cell carcinoma currently includes sunitinib. A barrier to long-term treatment with... 
TRIAL | THERAPY | PAZOPANIB | ONCOLOGY | TOLERABILITY | GUIDELINES | TOXICITY | EXPERIENCE | DOSING SCHEDULE
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2019, Volume 30, Issue 2, pp. 317 - 324
Abstract Background Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt)... 
Phase II | Pazopanib | Trametinib | Braf wild-type | Melanoma | trametinib | SURVIVAL | phase II | NRAS | MEK INHIBITION | ONCOLOGY | melanoma | SELUMETINIB | BRAF wild-type | pazopanib | DOCETAXEL | CANCER | Original
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2019, Volume 25, Issue 12, pp. 3486 - 3494
Purpose: No antiangiogenic treatment is yet approved for extrapancreatic neuroendocrine tumors (NET). Surufatinib (HMPL-012, previously named sulfatinib) is a... 
DIAGNOSIS | EVEROLIMUS | PAZOPANIB | ONCOLOGY | BEVACIZUMAB | SUNITINIB | DEPOT OCTREOTIDE | INHIBITOR
Journal Article
The Oncologist, ISSN 1083-7159, 01/2018, Volume 23, Issue 1, pp. 62 - 70
Background Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib and... 
Chemotherapy | Sarcoma | Trabectedin | Alveolar soft part sarcoma | Pazopanib | SOLID TUMORS | EFFICACY | TISSUE SARCOMA | PHASE-II | ANTITUMOR-ACTIVITY | METASTATIC LIPOSARCOMA | ONCOLOGY | SUNITINIB | MUSCULOSKELETAL ONCOLOGY GROUP | TUMOR MICROENVIRONMENT | Sarcomas
Journal Article
Journal of Pediatric Hematology/Oncology, ISSN 1077-4114, 2018, p. 1
Axial skeleton primary tumor, metastatic disease at presentation, incomplete surgical resection, and <90% tumor necrosis have all been known to influence... 
relapsed | pediatric osteosarcoma | pazopanib | MAP | oncology
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 06/2016, Volume 43, Issue 6, pp. 785 - 787
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 09/2017, Volume 104, Issue 9, pp. 705 - 706
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2014, Volume 32, Issue 33
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 12/2014, Volume 37, Issue 12, pp. 795 - 795
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.